1,3-Dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one → 1-[1-(3-{1-[5-Chloro-2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-yl}benzoyl)piperidin-4-yl]-1,3-dihydrobenzoimidazol-2-one

Participants

Role	Name	HCID	Charge
Reactant	1,3-Dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one	HCID 88638	—
Reactant	3-{1-[5-Chloro-2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-yl}benzoic acid	HCID 58327807	—
Product	1-[1-(3-{1-[5-Chloro-2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-yl}benzoyl)piperidin-4-yl]-1,3-dihydrobenzoimidazol-2-one	HCID 58327863	—

Reaction Steps

(3-{1-[5-chloro-2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-yl}benzoic acid was reacted with 1,3-dihydro-1-(4-piperidinyl)benzoimidazol-2-one as in General Procedure 10 to give the title compound. LCMS: m/z=647.02 (M+H+); retention time=0.83 minutes.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US08080561B2
Source dataset	uspto-grants-2011_12
ORD ID	ord-30d14510a9ff4d148518b75c294747f4
Source note	uspto-grants-2011_12